A new way to examine stress and inflammation in the heart will help Parkinson’s researchers test new therapies and explore an unappreciated way the disease puts people at risk of falls and hospitalization.

Endologix Inc. announced one-year results from the LUCY (Evaluation of FemaLes who are Underrepresented Candidates for Abdominal Aortic AneurYsm Repair) registry at the 2018 Society for Vascular Surgery (SVS) Annual Meeting, June 21-23 in Boston. The LUCY study is the first to prospectively evaluate endovascular aneurysm repair (EVAR) outcomes in women who have more complex aortic anatomy and, subsequently, have worse reported outcomes than men undergoing EVAR. The results of the LUCY one-year data expand on the 30-day results presented last year, showing that at least 28 percent more women are eligible for minimally-invasive EVAR when using the Ovation Abdominal Stent Graft System than when using other EVAR systems.

Boston Scientific Corp. recently announced a definitive agreement to acquire Cryterion Medical Inc., a privately-held company developing a single-shot cryoablation platform for the treatment of atrial fibrillation (AF). The addition of this cryoballoon platform positions the company as the first to have both cryothermal and radiofrequency (RF) single-shot, balloon-based ablation therapies in its portfolio.

Intact Vascular Inc. announced the publication of the iDissection Classification trial results in the current issue of Journal of Invasive Cardiology.

CathWorks announced the approval of a new Current Procedural Terminology (CPT) code 0523T for non-invasive, 3-D FFRangio-enabled interpretation of possible atherosclerotic stenosis during coronary angiography interventions. The company said the code issuance is a major step forward in helping physicians objectively and cost-effectively determine if percutaneous coronary intervention (PCI) is indicated and revascularization has occurred in every coronary angiography procedure.

French-based CorWave announced that its CALYPSO program has received 14 million euros to develop CorWave Neptune, a new type of cardiac support to improve the management of patients with severe heart failure. The CALYPSO Research and Development (R&D) program, with a total budget of 25 million euros over 4 years, will be partially financed with 14 million euros support from the Programme d'Investissements d'Avenir (Future Investments Program), managed by the Secrétariat Général pour l’Investissement (General Secretariat for Investment – SGPI) and operated by Bpifrance.